Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story Lacea Loader | Photo Sonia Small (Kaleidoscope Studios)
Dr Engela van Staden
Dr Engela van Staden, Vice Rector: Academic

The University of the Free State (UFS) has finalised the first part of the Council on Higher Education (CHE) Institutional Audit (IA), submitting its Institutional Self-Evaluation Report (SER) and Portfolio of Evidence (PoE) to the higher education quality assurance body. 

According to Dr Engela van Staden, Vice-Rector: Academic, the second part of the institutional audit will involve the participation of relevant stakeholders in a site visit to the institution. During the visit, scheduled between 9 and 13 May 2022, an external panel of experts will systematically assess the submitted SER and requisite documents by asking inquisitive questions to interviewees who will be participating in this process.  

“The focus will be on the quality of programme offerings with a view to improving student success in all spheres of the student walk – from registration to graduation. To this end, the university’s Integrated Quality Management Framework (IQMF) will be assessed in order to provide evidence that quality assurance is ingrained in the core functions of the UFS, i.e., student success; quality of teaching and research; and engaged scholarship.”

Dr Van Staden says by re-introducing the SER, the university will embark on a stakeholder engagement plan, engaging with staff in faculties, service units, directorates, centres, departments, or schools, to keep them informed and prepared for a productive contribution to the Institutional Audit process. 

- The CHE is an independent statutory body established in terms of the provisions of the Higher Education Act No. 101 of 1997, as amended. It advises the Minister responsible for Higher Education and Training and is the national authority for quality assurance and promotion in higher education.

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept